CHMCC Pediatric Pharmacology Research Unit

描述(由申请人提供)： 辛辛那提儿童医院医疗中心(CCHMO PPRU)网络网站在上一个资金周期中已发展成为主要的儿科临床药理学项目，拥有集中的神经药理学专业知识。自1999年以来，CCHMC PPRU要么引入了网络，要么在每一项神经药理学方案中发挥了关键的设计和实施作用。它的成熟发展体现在儿科临床药理学奖学金培训计划WATT、任何机构中最集中的委员会认证的儿科临床药剂师、扩大的核心湿法和干法实验室设施以及专门的临床研究空间，以改进我们的计划和网络参与。我们网站的资源包括：1)儿科GCRC，2)非营利性临床试验组织和基础设施，3)专注于环境遗传学的儿科中心，4)Howard Hughes生物信息学中心，5)CERT(治疗学教育和研究中心)，6)疫苗测试和治疗中心，7)流行病学和生物统计中心，8)新生儿网络网站和9)药物遗传学实验室。 CHMCC PPRU位于橡树临床研究设施内新装修的空间内，由连续的18个门诊检查室组成(10,000平方米。FT)，核心实验室(3500平方英尺英国《金融时报》)和行政(2400平方英尺)英国《金融时报》)同时，MH资助的儿科GCRC提供住院能力。CHMCC PPRU由儿童精神病学家/临床药理学家Sallee博士领导，他在临床试验的所有方面都有丰富的经验，并与制药业和FDA建立了现有的联系。Vinks博士是核心实验室主任和研究员培训主任，他通过药物动力学、药物动力学建模和分析能力补充了这一专业知识。联合调查员Tracy Glauser(儿科神经科医生)、Phil Walson(儿科临床药剂师)和Dan Nebert(儿科临床药剂师)与PPRU单位密切合作，积极参与方案设计、实施、培训和教育活动。继续关注儿科神经药理学的优势被我们的两个网络提案所证明：“利培酮在普及性发育障碍中的药物遗传学”(Vinks博士；儿童失神癫痫的药物遗传学和药效学“Glauser博士。

DESCRIPTION (provided by applicant): The Cincinnati Children's Hospital Medical Center (CCHMO PPRU) Network site has developed into a premier pediatric clinical pharmacology program during the previous funding cycle, with concentrated expertise in neuropharmacology. CCHMC PPRU has either brought to the Network, or played key designlimplementation roles for every neurophamiacology protocol since 1999. It's mature development is exemplified by a pediatric clinical pharmacology fellowship training program watt, the highest concentration of board-certified pediatric clinical pharmacologists of any institution, expanded core wet and dry lab facilities, and dedicated clinical studies space to improve our program and network participation. The confluence of resources at our site include: 1) a pediatric GCRC, 2) a not-for-profit clinical trials organization and infrastructure, 3) a pediatric focused Center for Environmental Genetics, 4) a Howard Hughes Bioinformatics center, 5) a CERT (Center for Education and Research in Therapeutics), 6) a Vaccine Testing and Treatment center, 7) a Center for Epidemiology and Biostatistics, 8) a Neonatal Network site and a 9) Pharmacogenetics lab. The CHMCC PPRU is situated in newly renovated space within the Oak Clinical Research Facility and consists of contiguous 18 outpatient exam rooms (10,000 sq. ft.), core laboratory (3500 sq. ft.) and administrative (2400 sq. ft.) space while an MH funded pediatric GCRC provides inpatient capability. The CHMCC PPRU is directed by Dr. Sallee, a child psychiatrist/clinical pharmacologist, with extensive experience in all aspects of clinical trials and with existing linkages to the pharmaceutical industry and FDA. Dr. Vinks, core laboratory director and fellowship training director complements this expertise with pharmacokineticlpharmacodynarnic modeling and analytic capability. Co-investigators, Tracy Glauser (pediatirc neurologist), Phil Walson (pediatric clinical phannacologist) and Dan Nebert (pediatric clinical pharmacologist), work closely with the PPRU unit and actively contribute to protocol design, implementation, training, and educational activities. Advantages of continuing a focus on pediatric neuropharmacology is documented by our two network proposals; "Pharmacogenetics of Risperidone in Pervasive Development Disorder" (Dr. Vinks; Pharmacogenetics and Pharmacodynamics of Childhood Absence Epilepsy" Dr. Glauser.